CONCANAMYCIN A Property

Melting point:

179-180℃ (dichloromethane ethanol )

Boiling point:

966.4±65.0 °C(Predicted)

Density 

1.20±0.1 g/cm3(Predicted)

storage temp. 

−20°C

solubility 

Soluble in DMSO

pka

12.46±0.70(Predicted)

form 

Lyophilized solid

color 

White

BRN 

3560277

Stability:

Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.

Safety

Hazard Codes 

T+

Risk Statements 

26/27/28-36

Safety Statements 

26-36/37/39-45

RIDADR 

UN 3462 6.1/PG 2

WGK Germany 

3

RTECS 

CB9732000

F 

10-21

HazardClass 

6.1(b)

PackingGroup 

III

HS Code 

2941900000

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H319Causes serious eye irritation

Precautionary statements

P262Do not get in eyes, on skin, or on clothing.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

CONCANAMYCIN A Chemical Properties,Usage,Production

Description

Concanamycin A (80890-47-7) is a potent and specific inhibitor of the vacuolar (V-type) H+-ATPase which can induce apoptotic cell death in various cell lines.1,2?Inhibits cell surface expression of virus envelope glycoproteins.3?Dramatically increases the rate of extracellular vesicle release from a variety of cell types.4?Inhibits autophagy by blocking lysosomal acidification.5

Uses

Concanamycin A is the major analogue of the concanamycin complex produced by Streptomyces sp.. It has been shown to act as a potent and specific vacuolar-ATPase inhibitor. Concanamycin A inhibits the acidification of organelles and blocks cell surface expression of viral envelope glycoproteins without affecting their synthesis. It also interferes with intracellular protein trafficking and inhibits perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. Concanamycins are structurally related to the bafilomycins.

Uses

Concanamycin A has been used:

• as a lysosomal inhibitor in young and old fibroblasts
• as a vacuolar-type H⁺-ATPase inhibitor in presynaptic vesicles
• as a lysosomal acidification blocker in HepG2 hepatocytes cells

Definition

ChEBI: A concanamycin in which the lactone ring contains 4 double bonds and is substituted by 4 methyl groups, 2 hydroxy groups, 2 methoxy groups and an ethyl group.

General Description

Chemical structure: macrolide

Biological Activity

Specific inhibitor of V-type (vacuolar) H + -ATPase that displays > 2000-fold selectivity over other H + -ATPases (IC 50 values are 9.2, > 20000, > 20000 and > 20000 nM for yeast V-type, F-type, P-type H + -ATPases and porcine P-type Na + ,K + -ATPase respectively). Blocks cell surface expression of virus envelope glycoproteins without affecting synthesis and exhibits cytotoxicity in several cell lines.

Biochem/physiol Actions

Concanamycin A (ConA) inhibits acidification of organelles and perforin-mediated cytotoxicity. It is a vacuolar-type v-ATPase inhibitor. ConA possesses antiprotozoal and antineoplastic properties. It mediates inhibition of the negative factor (Nef) protein of the human immunodeficiency virus.

storage

Store at -20°C

References

1) Nishihara?et al.?(1995),?Specific inhibitors if vacuolar type H(+)-ATPases induce apoptotic cell death; Biochem. Biophys, Res. Commun.,?212?255 2) Hong?et al. (2006),?Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells; J. Pharmacol. Exp. Ther.,?319?672 3) Muroi?et al.?(1993),?Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus; Cell Struct. Function,?18?139 4) Cashikar and Hanson (1987),?A cell-based assay for CD63-containing extracellular vesicles; PLoS One,?14?e0220007 5) Gradzka?et al.?(2018),?Inhibitor of apoptosis proteins are required for effective fusion of autophagosomes with lysosomes; Cell Death Dis.,?9?529